Anaplastic lymphoma kinase (ALK) rearrangement-positive non-small-cell lung cancers can be effectively treated with an ALK tyrosine kinase inhibitor (TKI) such as crizotinib, but the response magnitude and duration are heterogeneous. Several ALK variants have been identified, but few studies have focused on the effects of different ALK variants on the efficacy of crizotinib.
Patients and Methods
Among 55 patients treated with crizotinib as the initial ALK-TKI between January 2007 and December 2014, we identified 35 patients with tumor specimens that could be evaluated for ALK variants by reverse transcription polymerase chain reaction. We retrospectively evaluated the efficacy of crizotinib on the basis of the objective response rate and progression-free survival (PFS) according to the ALK variants.
Results
The most frequent ALK variant was variant 1 in 19 patients (54%), followed by variant 2 in five patients (14%), variant 3a/3b in four patients (12%), and other variants in seven patients (20%).
Objective response rate was 69% in all patients, whereas it was 74% and 63% in the variant 1 and non-variant 1 groups, respectively. The median PFS time was significantly longer in patients with variant 1 than in those with non-variant 1 (median PFS, 11.0 months [95% CI, 6.5 to 43.0 months] v 4.2 months [95% CI, 1.6 to 10.2 months], respectively; P , .05). Multivariable analysis identified two significant factors associated with PFS duration, ALK variant 1 (hazard ratio, 0.350; 95% CI, 0.128 to 0.929; P , .05) and advanced stage (hazard ratio, 4.646; 95% CI, 1.381 to 21.750; P , .05).
Conclusion
Our results indicate the better efficacy of crizotinib in patients with ALK variant 1 versus non-variant
INTRODUCTION
Anaplastic lymphoma kinase (ALK) gene rearrangements are present in approximately 5% of non-small-cell lung cancers (NSCLCs). 1,2 These rearrangements occur because of a chromosomal inversion within the short arm of chromosome 2, which results in the formation of the echinoderm microtubule-associated protein-like 4 (EML4) -ALK fusion oncogene. However, this chromosomal inversion does not always occur in the same location. Several EML4-ALK variants have been described, and the most frequent are variant 1 (33%), where exon 13 of EML4 is fused to exon 20 of ALK (E13;A20); variant 2 (10%), where exon 20 of EML4 is fused to exon 20 of ALK (E20; A20); and variant 3a/b (29%), where exon 6a or 6b of EML4 is fused to exon 20 of ALK (E6a/b; A20).
3-5 All variants contain exons 20 to 29 of ALK fused to a varying proportion of EML4. 6 EMLs are believed to represent a class of microtubule destabilizers, although their exact functions remain unknown. 7 The proportion of EML4 fused to the kinase domain of ALK varies depending on the respective fusion variant, but the aminoterminal coiled-coil domain within EML4 is necessary and sufficient for the transforming activity of EML4-ALK via homodimerization and kinase activation.
2 Recently, Wiesner et al 8 reported a novel mechanism of ALK activation through the splicing variant that constitutes the kinase domain but lacks the coiled-coil domain. This type of mechanism may contribute to molecular pathogenesis in addition to ALK translocation, although its frequency is rare in lung cancer. All previously reported EML4-ALK fusion variants have been shown to be oncogenic and induce ALK dependency. 6, 9 Because the activity ALK tyrosine kinase is necessary for its transforming activity and oncogenicity, ALK inhibitors have been identified as potential clinical therapies, which are currently being evaluated in preclinical models both in vitro and in vivo. Moreover, several non-EML4 fusion genes have been identified, including kinesin family member 5B (KIF5B), TRK-fused gene (TFG), kinesin light chain 1 (KLC1), Huntingtin-interacting protein 1 (HIP1), translocated promoter region (TPR), suppressor of cytokine signaling 5 (SOCS5), and baculoviral inhibition of apoptosis protein repeat containing 6 (BIRC6), although their exact frequency and clinical significance are still being investigated. [10] [11] [12] [13] [14] [15] [16] [17] Crizotinib was the first ALK tyrosine kinase inhibitor (TKI) approved for ALK-rearranged NSCLCs. Compared with standard cytotoxic chemotherapy, the randomized phase III PROFILE 1007 and 1014 trials showed that crizotinib can lead to improved outcomes, such as progression-free survival (PFS), and better quality-of-life measurements. 18, 19 However, despite the significant clinical response to crizotinib when controlling systemic sites with a tumor burden in patients with ALK-rearranged NSCLC, all patients treated with crizotinib developed resistance. The mechanism of acquired resistance has been identified, and it includes ALK gene alterations, such as ALK point mutations and copy number gain 20,21 as well as the activation of bypass signaling via the activation of other oncogenes.
22,23
In ALK-rearranged NSCLC, it is still unclear whether different variants can affect the therapeutic efficacy of ALK inhibition. Epidermal growth factor receptor (EGFR) mutations are the most frequent targeted key growth driver mutations in NSCLCs, and the activity of EGFR-TKIs has been reported to differ among various types of EGFR mutations.
24-28 Therefore, the aim of this study was to evaluate whether the efficacy of crizotinib differs among ALK variants.
PATIENTS AND METHODS

Patients
Between January 2007 and December 2014, 79 consecutive patients with advanced ALK-positive NSCLC were treated with an ALK inhibitor at our institution, where 55 of the patients were treated with crizotinib as the initial ALK inhibitor. Among these 55 ALK-positive patients treated with crizotinib, we identified 35 patients with tumor specimens that could be evaluated for ALK variants by reverse transcription polymerase chain reaction (RT-PCR), whereas the other 44 patients were excluded from this study as a result of a lack of fusion data or different initial ALK inhibitors, such as alectinib or ceritinib. The ALK gene rearrangement status was assessed by fluorescent in situ hybridization (FISH), RT-PCR, or immunohistochemistry (IHC). We screened all patients with NSCLC, including those with squamous cell carcinoma, on the basis of the results of FISH, RT-PCR, or IHC at our institution and considered that a tumor was ALK positive when at least two of the FISH, RT-PCR, or IHC tests had positive results. Among the 35 patients who could be evaluated to detect ALK variants by RT-PCR, 25 patients were concurrently assessed by FISH and 28 patients were assessed by IHC. The 19 patients assessed using both FISH and IHC were all ALK positive. These 35 patients were retrospectively evaluated on the basis of patient characteristics, initial response to crizotinib, and progression patterns during radiographic assessment of progressive disease (PD) as defined by the Response Evaluation Criteria in Solid Tumors (RECIST). The progression date was defined on the basis of routine surveillance imaging. We divided the patients into ALK variant 1 and non-variant 1 groups because ALK variant 1 is the most common variant in ALK-positive NSCLC. 4, 29 This study was approved by the Institutional Review Board of the Aichi Cancer Center.
RT-PCR to Determine ALK Rearrangements
Tumor tissue was obtained from surgical resection or initial diagnosis biopsy, and it was used as the starting material for total RNA extraction with an RNeasy Mini Kit and RNase-Free DNase Set (Qiagen, Hilden, Germany). The RNA samples were then analyzed with a one-step RT-PCR kit (Qiagen) to detect the EML4-ALK fusion transcripts. The sequences of the PCR primers were as follows: F1, 59-GTCAGCTCTTGAGTCAC-GAGTT-39; F2, 59-GTGCAGTGTTTAGCATTCTTGGGG-39; and R1, 59-ATCCAGTTCGTCCTGTTCAGAGC-39. The thermal cycle conditions used to detect the EML4-ALK fusion transcripts comprised cDNA synthesis at 50°C for 20 minutes, denaturation at 95°C for 15 minutes, 40 cycles of denaturation at 95°C for 30 seconds, annealing at 60°C for 50 seconds, strand elongation at 72°C for 50 seconds, and a final elongation step at 72°C for 5 minutes. All PCR products were subjected to Sanger sequencing to confirm the presence of the EML-ALK and ALK variant. In this study, we did not examine all non-EML4 fusions. All of the positive tumors identified by RT-PCR were confirmed by Vysis ALK Break Apart FISH analysis (Abbott Molecular, Des Plaines, IL) and/or ALK IHC. 42 
Evaluation of Crizotinib Efficacy
The initial dose of crizotinib was 250 mg twice per day, and the drug was orally administered until PD or unacceptable toxicity. Patients who experienced toxicity underwent dose reduction or interruption. The objective tumor response was evaluated according to the radiographic assessment using RECIST version 1.1. 30 The objective response rate (ORR) was calculated as the total percentage of patients with a complete response or partial response (PR). The disease control rate was calculated as the total percentage of patients with complete response, PR, or stable disease.
Statistical Analysis
All of the statistical analyses were performed using JMP for Windows version 9 statistical software package (SAS Institute, Cary, NC). Differences in baseline characteristics between groups were compared using the x 2 or Fisher's exact test for categorical data, as appropriate. PFS was measured from the start of crizotinib administration until the date of RECIST PD. We regularly monitored brain metastases in a routine follow-up imaging study, but the frequency and monitoring methods could vary. The survival probabilities were estimated using the Kaplan-Meier method, where differences in the variables were calculated using the log-rank test. Multivariable regression analysis was conducted according to the Cox proportional hazards model. Covariates with P #.20 in the univariable analysis were included in the multivariable model. All P values were two-sided, and P , .05 was considered statistically significant, unless stated otherwise.
RESULTS
Patient Characteristics
Patient characteristics are listed in Table 1 . The median age was 57 years (range, 26 to 80 years), and 13 patients (37%) were men. Thirty patients (86%) had an Eastern Cooperative Oncology Group performance status of 0 or 1. Histologic examination detected adenocarcinoma in all of the patients, among whom 26 had stage IIIB and IV disease. Crizotinib was administered to 35 patients; 10 patients (29%) received the drug as a first-line treatment of advanced or recurrent disease, 18 patients (51%) received it as a second-line treatment, and seven patients (20%) received it as a third-line or later treatment. According to the status of brain metastasis, seven patients (20%) had brain metastasis before treatment with crizotinib. Among the 35 patients, 24 (69%) had PR, four (11%) had stable disease, and five (14%) had PD. The response could not be evaluated in two patients in whom crizotinib was discontinued because of toxicity before the first tumor response evaluation. ORR was 69% among all patients. The median PFS time in all patients was 9.7 months. Figure 1 shows the specific features of the group according to the type of ALK variant. The most frequent ALK variant was variant 1, which was observed in 19 patients (54%), followed by variant 2 in five patients (14%), variant 3a/3b in four patients (12%), and other variants in seven patients (20%). Table 2 lists the clinical characteristics according to the variant status. Comparable clinical characteristics were observed in the variant 1 and non-variant 1 groups. ORRs with crizotinib were 74% and 63% in the variant 1 and non-variant 1 groups, respectively (P = .7160). A significantly greater proportion of patients with ALK variant 1 achieved disease control than those with non-variant 1 (95% v 63%, respectively; P = .0318). The median PFS time was significantly longer in patients with variant 1 than in patients with non-variant 1 (11.0 months [95% CI, 6.5 to 43.0 months] v 4.2 months [95% CI, 1.6 to 10.2 months, respectively; P , .05; Fig 2) . Figure 3 shows the details of PFS according to the different types of ALK variant status. Table 3 lists the results of the univariable and multivariable analyses used to determine the predictive factors for PFS. The univariable analysis showed that the variant type, stage, and performance status were significant factors for PFS. The multivariable analysis identified two factors associated with the duration of PFS; these were ALK variant 1 (hazard ratio, 0.350; 95% CI, 0.128 to 0.929; P , .05) and advanced stage (hazard ratio, 4.646; 95% CI, 1.381 to 21.750; P , .05).
Clinical Outcomes With Variant 1 and Non-Variant 1
Progression Patterns
At the time of the analysis, 25 patients (71%) treated with crizotinib exhibited PD. Among these 25 patients, recurrences in the CNS were the most common relapse pattern, observed in 14 patients (56%). The rates of CNS recurrence were 53% in the variant 1 group and 58% in the non-variant 1 group. There were no significant differences in the patients with CNS relapse. There were also no significant differences in the intrathoracic and extrathoracic recurrences between the variant 1 and nonvariant 1 groups.
Safety and Adverse Events
We graded adverse events according to Common Terminology Criteria for Adverse Events, version 4.0. Among the 35 patients, 24 patients (69%) were treated with crizotinib without dose reduction. Appendix Table A1 (online only) lists patients with greater than grade 2 treatment-related adverse events among the 35 patients who were primarily treated with 250 mg twice per day. Twelve patients experienced greater than grade 2 treatment-related events, which comprised elevated ALT and AST (n = 5, including two patients with grade 4), nausea and vomiting (n = 3), decreased appetite (n = 1), hyponatremia (n = 1), and esophageal ulceration (n = 2). Two patients permanently discontinued the study because of grade 4 increases in AST and ALT (one patient with variant 1 and one patient with non-variant 1). Nine patients (7%) required dose reduction as a result of treatment-related adverse events (increases in ALTor ASTor both, n = 3; nausea and vomiting, n = 3; decreased appetite, n = 1; hyponatremia, n = 1; and esophageal ulceration, n = 1, including seven patients with variant 1 and two patients with non-variant 1). No patients permanently discontinued the treatment because of treatment-related adverse events. There was no significant difference in the frequency of treatment-related dose reduction or interruption of crizotinib (P = .167).
DISCUSSION
Our study showed that patients with ALK variant 1 had a significantly longer PFS with crizotinib than patients with non-variant 1, which was also verified by multivariable analysis. There were no significant differences in the progression patterns during treatment with crizotinib according to the analysis based on the ALK variant status. A few previous studies have performed detailed evaluations of the ALK variant status and response to crizotinib in patients with ALK-positive NSCLC in clinical settings. [31] [32] [33] We analyzed the phase I data of crizotinib in ALK-positive NSCLC, 34 which showed that 12 (92%) of 13 patients with variant 1 had PRs and five (71%) of seven patients with non-variant 1 had PRs. Thus, there was no correlation between the variants and ORR. This trial included a small number of patients and only evaluated the correlation between ORR and variants. Similarly, we could access the response to treatment according to different variants in previous reports, but our study is characterized by analyzing the correlation between PFS and variant in detail first.
EGFR mutations are the most frequently targeted key growth driver mutations in NSCLC, and the activity of EGFR-TKIs has been reported to differ among various types of EGFR mutations.
24-28 Studies on the common EGFR mutations (deletion mutations in exon 19 [Del19] and the Leu858Arg point mutation in exon 21 [L858R]) have shown that there is no significant difference in the prognosis with L858R and Del19 mutations in patients with surgically resected NSCLC without any TKI treatment, 35 but Del19 mutations are associated with more effective EGFR-TKI therapy than L858R mutations. 36, 37 In addition, the Lux-Lung 3 and Lux-Lung 6 trials, which compared afatinib with chemotherapy in randomized phase III studies, indicated that the second-generation EGFR-TKI afatinib significantly improves overall survival compared with chemotherapy among patients with Del19, but not for patients with L858R disease, in whom the clinical benefit of afatinib over chemotherapy was demonstrated in terms of PFS and objective response. 38 Therefore, the difference in prognosis between EGFR Del19 and L858R disease might be related to the efficacy of the EGFR-TKIs.
Furthermore, GI stromal tumor constitutively expresses activating mutant isoforms of KIT or kinase platelet-derived growth factor receptor a, which are therapeutic targets for imatinib. No significant difference was reported in the prognosis after surgery in patients with KITexon 9 and exon 11 mutations, 39 but KITexon 11 mutations were associated with favorable clinical responses to imatinib in terms of ORR and time to tumor progression compared with KIT exon 9 mutations and wild-type genotype. 40 Given the differences in sensitivity to the TKIs, we attempted to evaluate the responsiveness of various ALK variants to crizotinib according to the EGFR mutation in NSCLC and KIT mutation status in GI stromal tumor.
Heuckmann et al 33 examined the differences in sensitivity to ALK inhibitors, such as crizotinib, in various types of ALK variants. In their in vitro study using the Ba/F3 cell line, they showed that variants 1 and 3b exhibited no significant differences in terms of the half-maximal growth inhibitory concentration of crizotinib, whereas variant 2 was significantly more sensitive to ALK inhibition than variant 3b. In addition, they found that different variants affected the overall fusion protein stability, inhibitorinduced protein degradation, and drug sensitivity. Recently, Hrustanovic et al 41 demonstrated the activation of different downstream molecules in lung adenocarcinoma cell lines (ie, H3122 harboring a variant 1 type EML4-ALK and H2228 with variant 3b). Compared with H3122, crizotinib failed to suppress RAS-GTP, p-ERK, or cell viability in H2228, and thus the half-maximal growth inhibitory concentration for crizotinib was higher in H2228 than in H3122. This difference was caused by the lack of a HELP domain in EML4 in variant 3, of which the molecule enhances activation of the RAS-MAPK signaling pathway. These findings support those obtained in our study, which showed that different ALK variants might influence the response duration of crizotinib in ALK-positive NSCLC. However, it is unclear whether these in vitro observations can be used to predict actual clinical outcomes.
In this study, we found no difference in ORR between the variant 1 group, which is the common variant observed in ALKpositive NSCLC, and the non-variant 1 group. Interestingly, we observed that patients with the ALK variant 1 exhibited a significantly longer PFS duration with crizotinib compared with the non-variant 1 patients. Moreover, a greater proportion of patients with ALK variant 1 achieved disease control than those with nonvariant 1. Further studies are required to elucidate whether different ALK variants can affect the therapeutic efficacy of ALK inhibitors.
The current study had several limitations. First, this was a retrospective study with a small sample size. Thus, the intervals between imaging studies were not as consistent as expected in a prospective study. Second, it is unclear whether the discrimination between variant 1, which is the most frequent ALK variant, and non-variant 1 is relevant. Third, the treatment line for crizotinib differed across studies. The results obtained from PROFILE 1014 and 1007 showed that although formal comparisons cannot be made across studies, the efficacy of crizotinib in patients treated in a first-line setting seemed to be greater than that in patients who received previous treatment with platinum-based chemotherapy (PFS for first line v second line, 10.9 v 7.7 months, respectively). 18, 19 In the current study, we showed that administration of crizotinib resulted in significantly longer PFS in patients with ALK variant 1 than in patients with non-variant 1 according to the multivariable analysis, which included treatment line as a factor (first line v non-first line). Moreover, it will be important to examine whether there are differences on the basis of the ALK variant status in the efficacy of next-generation ALK-TKIs, such as alectinib and ceritinib, which have been reported to have potent efficacy in patients with ALK-positive NSCLC, including against mutations that confer resistance to crizotinib. Recently, Ou et al 12 reported that a patient with NSCLC harboring the HIP1-ALK fusion variant was responsive to alectinib. In addition, evaluations of the association between the ALK variant status and efficacy of ALK inhibitors, including crizotinib, will be required in the future.
In conclusion, this study highlights the frequency of ALK variants and therapeutic efficacy of crizotinib according to the different variants in patients with ALK-positive NSCLC. Our multivariable analysis showed that there was a significant association between the ALK variant status and improvements in the duration of PFS under crizotinib. In addition, our results showed that in patients with variant 1, crizotinib treatments achieved better disease control than that in patients with non-variant 1. Therefore, the treatment strategy for ALK-positive NSCLC should be determined on the basis of the ALK variant status of the patient. Further multicenter, prospective studies will need to be performed to confirm the specific association between the ALK variant status and efficacy of crizotinib.
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